{"entity":{"id":"tumor-normal-vs-tumor-only-sequencing","kind":"term","name":"Tumor-normal versus tumor-only sequencing","aka":[],"tldr":"Comparing tumour and suitable normal DNA helps distinguish acquired changes from inherited ones.","summary":"A matched normal is a separately collected specimen from the same person chosen to represent constitutional DNA; normal is an analytical role, not a guarantee of uncomplicated cells; it differs from a healthy reference cohort.","asOf":"2026-11-10","links":[{"label":"Personalized genomic analyses for cancer mutation discovery and interpretation.","url":"https://pubmed.ncbi.nlm.nih.gov/25877891/"},{"label":"Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.","url":"https://pubmed.ncbi.nlm.nih.gov/28341590/"}],"tags":[],"related":["ngs"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["A matched normal is a separately collected specimen from the same person chosen to represent constitutional DNA; normal is an analytical role, not a guarantee of uncomplicated cells; it differs from a healthy reference cohort.","Evidence in the normal supports constitutional origin; adequate tumour and normal depth with no normal support supports somatic origin; inadequate normal depth leaves an attribution gap and absence there is uninformative.","Tumour-only workflows infer origin from population databases, allele fractions and models; rare germline variants may be absent from databases; a hotspot or familiar gene does not prove tumour-only origin.","In Jones et al. (2015), 815 tumour-normal pairs across 15 tumour types, germline changes in cancer-predisposing genes were found in 3% of patients with apparently sporadic cancers; tumour-only analysis could not definitively identify them and added false positives of 31% (targeted) and 65% (exome) of alterations.","Origin does not establish function, hereditary-risk conclusions or drug benefit; paired research sequencing is not a validated hereditary test.","Fictional teaching exercise: A tumour-only rare repair-gene variant at 48% allele fraction absent from databases cannot be labelled inherited or somatic from those facts; review copy state and attribution model.","Retain specimen identity, suitable normal tissue, extraction consumption, reference coordinates, both support counts and fractions, attribution rules and uncertainty. Normal sampling need not require a second tumour biopsy. Mismatch, contamination, low normal coverage and rare constitutional variants can mislead; validate the intended somatic/germline workflow and confirmation policy separately."],"category":"Genomics & genetics"},"route":"/terms/tumor-normal-vs-tumor-only-sequencing/","neighbours":{"term":[{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/"}]}}